Search research articles
Contact Us
Filters
Showing results (991-1000 of 1,006) with videos related to
Page
of 101
Sort By:
JAMA Oncology
|
February 14, 2020
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial
Rita Nanda, Minetta C Liu, Christina Yau, et al.
NPJ Breast Cancer
|
January 25, 2019
Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint
Judy C Boughey, Michael D Alvarado, Rachael B Lancaster, et al.
Research Square
|
November 19, 2025
WISDOM Randomized Trial Comparing Risk-Based Versus Annual Breast Cancer Screening: Study Cohort Characteristics and Design
Allison Fiscalini, Kelly Blum, Kirkpatrick Fergus, et al.
NPJ Breast Cancer
|
May 23, 2026
WISDOM randomized trial comparing risk-based versus annual breast cancer screening: study cohort characteristics and design
Allison Fiscalini, Kelly Blum, Kirkpatrick Fergus, et al.
Cancer Cell
|
June 18, 2021
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
Lajos Pusztai, Christina Yau, Denise M Wolf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2020
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial
A Jo Chien, Debasish Tripathy, Kathy S Albain, et al.
Nature Communications
|
November 6, 2021
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2<sup>+</sup> breast cancer in the adaptively randomized I-SPY2 trial
Amy S Clark, Christina Yau, Denise M Wolf, et al.
NPJ Breast Cancer
|
December 1, 2022
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer
Julie E Lang, Andres Forero-Torres, Douglas Yee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2023
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery
Kathy S Albain, Christina Yau, Emanuel F Petricoin, et al.
Genome Research
|
January 6, 2005
Comparative genome sequencing of Drosophila pseudoobscura: chromosomal, gene, and cis-element evolution
Stephen Richards, Yue Liu, Brian R Bettencourt, et al.
Page
of 101
Search research articles
Search
Showing results (991-1000 of 1,006) with videos related to
Sort By:
Page
of 101
JAMA Oncology
|
February 14, 2020
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial
Rita Nanda, Minetta C Liu, Christina Yau, et al.
NPJ Breast Cancer
|
January 25, 2019
Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint
Judy C Boughey, Michael D Alvarado, Rachael B Lancaster, et al.
Research Square
|
November 19, 2025
WISDOM Randomized Trial Comparing Risk-Based Versus Annual Breast Cancer Screening: Study Cohort Characteristics and Design
Allison Fiscalini, Kelly Blum, Kirkpatrick Fergus, et al.
NPJ Breast Cancer
|
May 23, 2026
WISDOM randomized trial comparing risk-based versus annual breast cancer screening: study cohort characteristics and design
Allison Fiscalini, Kelly Blum, Kirkpatrick Fergus, et al.
Cancer Cell
|
June 18, 2021
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
Lajos Pusztai, Christina Yau, Denise M Wolf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2020
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial
A Jo Chien, Debasish Tripathy, Kathy S Albain, et al.
Nature Communications
|
November 6, 2021
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2<sup>+</sup> breast cancer in the adaptively randomized I-SPY2 trial
Amy S Clark, Christina Yau, Denise M Wolf, et al.
NPJ Breast Cancer
|
December 1, 2022
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer
Julie E Lang, Andres Forero-Torres, Douglas Yee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2023
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery
Kathy S Albain, Christina Yau, Emanuel F Petricoin, et al.
Genome Research
|
January 6, 2005
Comparative genome sequencing of Drosophila pseudoobscura: chromosomal, gene, and cis-element evolution
Stephen Richards, Yue Liu, Brian R Bettencourt, et al.
Page
of 101